Steven Mintz is Director at Serina Therapeutics, Inc. (SER). They have made 5 open-market trades across 1 company since 2024, most recently 2024-09-12.
CIK 0002008741
5 open-market purchases totalling $290K since 2024, never a sale. Across 5 scored buys the stock is down 24.6% at ninety days, and 30.4 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| SER | 17,443 | $34K |
Shares reported on the most recent Form 4, priced at the 2024-09-16 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 20% | 40% | 0% |
| Avg Move | -2.7% | +0.8% | -24.6% |
| Alpha | -4.0% | -0.9% | -30.4% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SER | BUY | 2024-09-12 | 2024-09-16 | $6.47 | $39K | +17.4% | +19.2% | -34.5% |
| SER | BUY | 2024-08-15 | 2024-08-19 | $6.59 | $59K | -5.8% | -29.2% | -41.1% |
| SER | BUY | 2024-06-21 | 2024-06-27 | $9.33 | $71K | -9.7% | +23.4% | -13.5% |
| SER | BUY | 2024-05-21 | 2024-05-23 | $0.10 | $665 | -7.8% | -4.7% | -16.9% |
| SER | BUY | 2024-05-17 | 2024-05-23 | $9.76 | $121K | -7.8% | -4.7% | -16.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.